GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005110018 | Prostate | Tumor | negative regulation of binding | 52/3246 | 162/18723 | 3.22e-06 | 5.29e-05 | 52 |
GO:004339317 | Prostate | Tumor | regulation of protein binding | 60/3246 | 196/18723 | 3.36e-06 | 5.45e-05 | 60 |
GO:190401912 | Prostate | Tumor | epithelial cell apoptotic process | 41/3246 | 121/18723 | 7.85e-06 | 1.16e-04 | 41 |
GO:002240717 | Prostate | Tumor | regulation of cell-cell adhesion | 112/3246 | 448/18723 | 2.20e-05 | 2.80e-04 | 112 |
GO:005165014 | Prostate | Tumor | establishment of vesicle localization | 49/3246 | 161/18723 | 3.02e-05 | 3.62e-04 | 49 |
GO:000749211 | Prostate | Tumor | endoderm development | 28/3246 | 77/18723 | 5.01e-05 | 5.55e-04 | 28 |
GO:005067914 | Prostate | Tumor | positive regulation of epithelial cell proliferation | 58/3246 | 207/18723 | 8.47e-05 | 8.47e-04 | 58 |
GO:006156413 | Prostate | Tumor | axon development | 113/3246 | 467/18723 | 8.86e-05 | 8.74e-04 | 113 |
GO:000689816 | Prostate | Tumor | receptor-mediated endocytosis | 66/3246 | 244/18723 | 9.25e-05 | 9.05e-04 | 66 |
GO:005164813 | Prostate | Tumor | vesicle localization | 51/3246 | 177/18723 | 1.03e-04 | 9.96e-04 | 51 |
GO:003209114 | Prostate | Tumor | negative regulation of protein binding | 31/3246 | 94/18723 | 1.69e-04 | 1.50e-03 | 31 |
GO:000736912 | Prostate | Tumor | gastrulation | 52/3246 | 185/18723 | 1.76e-04 | 1.55e-03 | 52 |
GO:190313113 | Prostate | Tumor | mononuclear cell differentiation | 102/3246 | 426/18723 | 2.87e-04 | 2.32e-03 | 102 |
GO:000740913 | Prostate | Tumor | axonogenesis | 100/3246 | 418/18723 | 3.38e-04 | 2.70e-03 | 100 |
GO:000170411 | Prostate | Tumor | formation of primary germ layer | 36/3246 | 121/18723 | 5.22e-04 | 3.82e-03 | 36 |
GO:190403511 | Prostate | Tumor | regulation of epithelial cell apoptotic process | 30/3246 | 96/18723 | 6.03e-04 | 4.31e-03 | 30 |
GO:000715915 | Prostate | Tumor | leukocyte cell-cell adhesion | 89/3246 | 371/18723 | 6.33e-04 | 4.52e-03 | 89 |
GO:003362712 | Prostate | Tumor | cell adhesion mediated by integrin | 24/3246 | 72/18723 | 7.41e-04 | 5.13e-03 | 24 |
GO:004858814 | Prostate | Tumor | developmental cell growth | 60/3246 | 234/18723 | 8.41e-04 | 5.66e-03 | 60 |
GO:190303714 | Prostate | Tumor | regulation of leukocyte cell-cell adhesion | 81/3246 | 336/18723 | 9.26e-04 | 6.10e-03 | 81 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451017 | Prostate | BPH | Focal adhesion | 85/1718 | 203/8465 | 1.17e-12 | 2.28e-11 | 1.41e-11 | 85 |
hsa051658 | Prostate | BPH | Human papillomavirus infection | 111/1718 | 331/8465 | 6.15e-09 | 7.81e-08 | 4.83e-08 | 111 |
hsa0481020 | Prostate | BPH | Regulation of actin cytoskeleton | 80/1718 | 229/8465 | 1.23e-07 | 1.31e-06 | 8.10e-07 | 80 |
hsa0513518 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
hsa041515 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa0467028 | Prostate | BPH | Leukocyte transendothelial migration | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa045125 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa0514016 | Prostate | BPH | Leishmaniasis | 24/1718 | 77/8465 | 1.57e-02 | 4.42e-02 | 2.73e-02 | 24 |
hsa0451018 | Prostate | BPH | Focal adhesion | 85/1718 | 203/8465 | 1.17e-12 | 2.28e-11 | 1.41e-11 | 85 |
hsa0516513 | Prostate | BPH | Human papillomavirus infection | 111/1718 | 331/8465 | 6.15e-09 | 7.81e-08 | 4.83e-08 | 111 |
hsa04810110 | Prostate | BPH | Regulation of actin cytoskeleton | 80/1718 | 229/8465 | 1.23e-07 | 1.31e-06 | 8.10e-07 | 80 |
hsa0513519 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
hsa0415112 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa04670112 | Prostate | BPH | Leukocyte transendothelial migration | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa0451212 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa0514017 | Prostate | BPH | Leishmaniasis | 24/1718 | 77/8465 | 1.57e-02 | 4.42e-02 | 2.73e-02 | 24 |
hsa0451025 | Prostate | Tumor | Focal adhesion | 84/1791 | 203/8465 | 3.44e-11 | 6.69e-10 | 4.15e-10 | 84 |
hsa0481025 | Prostate | Tumor | Regulation of actin cytoskeleton | 84/1791 | 229/8465 | 3.40e-08 | 4.17e-07 | 2.58e-07 | 84 |
hsa0516522 | Prostate | Tumor | Human papillomavirus infection | 110/1791 | 331/8465 | 1.31e-07 | 1.51e-06 | 9.36e-07 | 110 |
hsa0415122 | Prostate | Tumor | PI3K-Akt signaling pathway | 105/1791 | 354/8465 | 7.42e-05 | 5.30e-04 | 3.28e-04 | 105 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGA4 | SNV | Missense_Mutation | | c.421A>G | p.Ile141Val | p.I141V | P13612 | protein_coding | tolerated(0.62) | benign(0.018) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
ITGA4 | SNV | Missense_Mutation | rs760310901 | c.1934N>G | p.Asn645Ser | p.N645S | P13612 | protein_coding | tolerated(0.48) | benign(0.077) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | novel | c.1641N>A | p.Ser547Arg | p.S547R | P13612 | protein_coding | tolerated(0.55) | benign(0.034) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | | c.2881N>T | p.His961Tyr | p.H961Y | P13612 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | novel | c.1660N>A | p.Glu554Lys | p.E554K | P13612 | protein_coding | tolerated(0.9) | benign(0) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
ITGA4 | insertion | Frame_Shift_Ins | novel | c.1639_1640insATAATATCTG | p.Ser547AsnfsTer13 | p.S547Nfs*13 | P13612 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGA4 | insertion | Frame_Shift_Ins | novel | c.183_184insG | p.Ala63GlyfsTer46 | p.A63Gfs*46 | P13612 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ITGA4 | deletion | Frame_Shift_Del | novel | c.1907delA | p.Lys636ArgfsTer5 | p.K636Rfs*5 | P13612 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGA4 | SNV | Missense_Mutation | novel | c.1364C>A | p.Ser455Tyr | p.S455Y | P13612 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ITGA4 | SNV | Missense_Mutation | | c.1370N>T | p.Ser457Phe | p.S457F | P13612 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | Vedolizmab | | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | PTG-100 | | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | VEDOLIZUMAB | VEDOLIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | CHEMBL1743087 | VEDOLIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | NATALIZUMAB | NATALIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | antibody | 178103204 | NATALIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | FIRATEGRAST | FIRATEGRAST | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | ATL1102 | | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | NATALIZUMAB | NATALIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | antagonist | CHEMBL2104967 | FIRATEGRAST | |